Skip to main content

Truvestments Capital LLC

Source: SEC Form 13F · as of Mar 2026

Truvestments Capital LLC holds 42 biotech & pharma companies tracked by BioSniper, totaling $2.0M in value as of Mar 2026 (SEC Form 13F).

Companies held

42

Total value held

$2.0M

BioSniper AIPage evidence connected

Prepared research question

What matters most for EXELIXIS, INC. (EXEL)—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

CompanySharesValue
EXELEXELIXIS, INC.7,726$331K
GILDGILEAD SCIENCES, INC.2,247$313K
CTMXCytomX Therapeutics, Inc.27,428$129K
PTGXProtagonist Therapeutics, Inc1,161$122K
ROIVRoivant Sciences Ltd.3,680$102K
KALVKalVista Pharmaceuticals, Inc.4,684$94K
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)1,701$94K
BBIOBridgeBio Pharma, Inc.1,155$86K
REGNREGENERON PHARMACEUTICALS, INC.105$81K
ARQTArcutis Biotherapeutics, Inc.3,012$71K
SNYSanofi1,461$70K
DMACDiaMedica Therapeutics Inc.9,849$67K
TGTXTG THERAPEUTICS, INC.1,621$54K
SMMTSummit Therapeutics Inc.2,603$49K
VCELVericel Corp1,534$49K
XERSXeris Biopharma Holdings, Inc.8,118$47K
ABEOABEONA THERAPEUTICS INC.10,307$46K
ORGOOrganogenesis Holdings Inc.13,323$32K
KNSAKiniksa Pharmaceuticals International, plc510$25K
ANIPANI PHARMACEUTICALS INC267$21K
ALNYALNYLAM PHARMACEUTICALS, INC.60$20K
ARGXARGENX SE26$19K
INSMINSMED Inc84$14K
OLMAOlema Pharmaceuticals, Inc.838$12K
RYTMRHYTHM PHARMACEUTICALS, INC.138$12K
VTGNVistagen Therapeutics, Inc.16,992$10K
XOMAXOMA Royalty Corporation290$9K
ARDXARDELYX, INC.1,057$6K
ACADACADIA PHARMACEUTICALS INC199$4K
PGENPRECIGEN, INC.578$2K
PVLAPALVELLA THERAPEUTICS, INC.14$2K
VKTXViking Therapeutics, Inc.42$1K
VYGRVoyager Therapeutics, Inc.330$1K
NGNENeurogene Inc.46$927
SANASana Biotechnology, Inc.300$864
ALDXAldeyra Therapeutics, Inc.265$448
PDSBPDS Biotechnology Corp655$396
PLRXPLIANT THERAPEUTICS, INC.50$63
IONSIONIS PHARMACEUTICALS INC1$56
RNAAtrium Therapeutics Inc.1$13
TVRDTvardi Therapeutics, Inc.4$13
AKTXAkari Therapeutics Plc1$5

13F holdings reflect long positions in U.S.-listed securities as reported to the SEC. Values are point-in-time for the most recent reported quarter.